baber/WOPTO huggingface dataset:
Patent NZ-328940-A (NZ)
Title: Methods and use t cell epitopes of lol p v ryegrass pollen antigens
Inventor: KNOX ROBERT BRUCE
IPC: A61K38/08
Filed: 1993-08-13
Abstract: The present invention provides isolated peptides of Lol p V, a major protein allergen of the species Lolium perenne. Therapeutic peptides within the scope of the invention comprise at least on T cell epitope, or preferably at least two T cell epitopes of a protein allergen of Lol p V. Diagnostic peptides within the scope of the invention bind IgE. The invention also provides modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or diagnosis of sensitivity to Lol p V or an allergen immunologically related to Lol p V in an individual. Therapeutic compositions comprising one or more peptides of the invention are also provided.
Patent NZ-331238-A (NZ)
Title: Method of promoting bone growth with hyaluronic acid and growth factors (bFGF)
Inventor: RADOMSKY MICHAEL
IPC: A61K31/728
Filed: 1997-03-05
Abstract: The specification describes a bone growth-promoting composition comprising hyaluronic acid and growth factor.  The composition has a viscosity and biodegradability sufficient to persist at a site of a desired bone growth and for a duration long enough to promote bone growth.
Patent NZ-333258-A (NZ)
Title: Bromotiacumicin antibiotic compounds
Inventor: HOCHLOWSKI JILL E
IPC: A61P31/04
Filed: 1997-06-24
Abstract: These bromotiacumicin antimicrobial compounds have the formula (I): where R1 and R2 are independently selected from the group consisting of hydrogen and C1-to-C4 alkanoyl; R3 and R4 are selected from the group consisting of (a) R3 is hydrogen and R4 is hydroxy, (b) R3 is hydroxy and R4 is hydrogen, (c) R3 and R4 taken together are =0; or (d)  selected from the group consisting of hydrogen and hydroxy; and R5 and R6 are independently selected from the group consisting of hydrogen, bromine and chlorine, with the proviso that at least one of R5 and R6 must be bromine. Also disclosed are pharmaceutical compositions comprising such compounds.
Patent NZ-334870-A (NZ)
Title: Bioconjugates having a bioactive agent and an organocobalt complex for to specific sites
Inventor: GRISSOM CHARLES B
IPC: A61K48/00
Filed: 1997-08-22
Abstract: The specification describes bioconjugates which comprise a bioactive agent and an organocobalt complex. The bioactive agent is covalently bonded directly or indirectly to the cobalt atom of the organocobalt complex. The bioactive agent is released from the bioconjugate by the cleavage of the covalent bond between the bioactive agent and the cobalt atom in the organocobalt complex. The cleavage may occur as a result of normal displacement by cellular nucleophiles or enzymatic action, but is preferably caused to occur selectively at a predetermined release site by application of an external signal. The external signal may be light or photoexcitation, i.e. photolysis, or it may be ultrasound, i.e. sonolysis. Further, if the photolysis takes places in the presence of a magnetic field surrounding the release site, the release of the bioactive agent into surrounding healthy tissue is minimized. Examples of targeting molecules include glucose, galactose, mannose, mannose 6phosphate, hormones (e.g., insulin, growth hormone, and the like), growth factors or cytokines (e.g., TGF-p, EGF, insulin-like growth factor, and the like), YEE(GalNAcAH)3 or derivatives, cobalamin, a-2 macroglobulins, asialoglycoprotein, albumin, texaphyrin, metallotexaphyrin, antibodies, antibody fragments (e.g., Fab), single-chain antibody variable region (scFv), transferrin, any vitamin and any coenzyme. The organocobalt complex is selected from the group consisting of an organo(pyridine)bis(dimethylglyoximato)cobalt, a corrinoid, or derivatives thereof.
Patent NZ-502114-A (NZ)
Title: Footwear shock absorbing system
Inventor: SERNA RALPH
IPC: A43B13/40
Filed: 1998-05-29
Abstract: A shock-absorbing cassette 20 for the midsole of an athletic shoe has a cassette base 27, first and second sets of cushion elements 21-22, 23-24, and a reduced height cushion element 25 between the first and second sets of cushion elements. The cushion elements are arranged to cushion the heel of the foot. The shock absorbing cassette may be part of a shoe sole shock absorbing system that also includes an insole board 8 having forefoot slits 9 to improve flexing, a thin midsole 10 with a heel pocket for seating the cassette, and a durable outsole 30.
Patent NZ-502386-A (NZ)
Title: Eraser for presentation board digitiser system, eraser surface contains microswitches
Inventor: ZLOTER YITZHAK
IPC: G06K9/00
Filed: 1998-02-25
Abstract: An eraser for a presentation board digitiser system includes two or more microswitches 180 in the eraser portion 168 that contacts the board.  This allows the system to determine how much of the eraser surface is touching the board, and therefore how much of the display to erase.  The microswitches are connected to infra-red or ultrasound transmitters, which transmit the state of the microswitches to the system controller.
Patent NZ-505740-A (NZ)
Title: Mixed waste processing plant whereby the speed of waste conveyed is higher prior to paper removal than the that prior to air sifting which in turn is higher than that prior to metal separation
Inventor: WUBBELS ALFONS
IPC: B29B17/04
Filed: 1998-12-22
Abstract: A method for processing mixed waste in a continuously operating processing plant comprising a plurality of successive stations which are connected to each other by means of at least one conveyor segment and wherein the mixed waste material is processed in at least one step and/or conveyed along at least one conveyor section, whereby the particles in the stream of mixed waste are accelerated at least in one transfer site between a conveyor section or one transfer site between two conveyor sections.
Patent NZ-505898-A (NZ)
Title: Powder preparations containing hydroxypyridones; useful for treating leg ulcers and/or decubitus ulcers
Inventor: BOHN MANFRED
IPC: A61P17/02
Filed: 1999-01-11
Abstract: The use of a powder comprising at least one 1-hydroxy-2-pyridone of the formula (I), wherein: R1, R2 and R3, which are identical or different, are H or alkyl with 1-4 carbon atoms; R4 is a saturated hydrocarbon radical with 6 to 9 carbon atoms or a radical of formula (II), wherein: X is S or O; Y is H or up to 2 halogen atoms such as chlorine and/or bromine; Z is a single bond or the divalent radicals O, S, -CR2-, in which R is H or (C1-C4)-alkyl, or other divalent radicals with 2-10 carbon atoms and, where appropriate, O and/or S atoms linked in the form of a chain, it being necessary - if the radicals contain 2 or more O and/or S atoms - for the latter to be separated from one another by at least 2 carbon atoms, and it also being possible for 2 adjacent carbon atoms to be linked together by a double bond, and the free valencies of the C atoms being saturated by H and/or (C1-C4)-alkyl groups; Ar is an aromatic ring system which has up to two rings and which may be substituted by up to three radicals from the group of fluorine, chlorine, bromine, methoxy, (C1-C4)-alkyl, trifluorormethyl and trifluoromethoxy, for the production of a pharmaceutical for the treatment of leg ulcers and/or decubitus ulcers.
Patent NZ-507560-A (NZ)
Title: Hydroxamic acid derivatives as antibacterials
Inventor: HUNTER MICHAEL GEORGE
IPC: A61K31/167
Filed: 1999-05-14
Abstract: Compounds of formula (I) are antibacterials wherein: R1 represents hydrogen, or C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms, amino, hydroxy, or C1-C6 alkoxy; R2 represents a group R10-(X)n-(ALK)m- wherein R10 represents hydrogen, or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by C1-C6 alkyl, C1-C6 alkoxy, hydroxy, mercapto, C1-C6 alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, -COOH, -CONH2, -COORA, -NHCORA, -CONHRA, -NHRA, -NRARB, or -CONRARB wherein RA and RB are independently a C1-C6 alkyl group, and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages, X represents -NH-, -O- or -S-, and m and n are independently 0 or 1; and A represents (i) a group of formula (IA), (IB), (IC) or (ID); R7 represents hydrogen, C1-C6 alkyl, or an acyl group.  Provided that: (a) R5 and R6 taken together with the nitrogen atom to which they are attached do not form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms when R1 and R3 are hydrogen, R2 is hydrogen, C1-C6 alkyl, phenyl, benyl, 4-chlorophenylmethyl, 4-nitrophenylmethyl, or 4-aminophenylmethyl and R3 is hydrogen, methyl, isopropyl or benzyl; and (b) R5 is not 2-pyridyl or 2-thiazolyl when R1 R3 and R6 are hydrogen, R2 is n-pentyl and R4 is methyl or isopropyl; and (c) R5 and R6 are not both ethyl when R1 and R3 are hydrogen, R2 is n-pentyl and R4 is methyl or isopropyl; or a pharmaceutically or veterinarily acceptable salt thereof in the preparation of a medicament for inhibiting bacterial growth.
Patent NZ-512556-A (NZ)
Title: Carburetor float bowl with ramp from fuel inlet to avoid splashing or slopping of fuel
Inventor: BRASWELL DAVID
IPC: F02M5/00
Filed: 2001-06-22
Abstract: In order to prevent fuel splashing and slopping a ramping surface is provided.
Patent NZ-519222-A (NZ)
Title: TNF-alpha antagonists and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
Inventor: LEE WYNE PUN
IPC: A61P25/28
Filed: 2000-12-14
Abstract: Disclosed are compositions comprising effective amounts of an LFA-1 antagonist and a TNF- alpha antagonist. Such compositions are useful in methods for the treatment of an LFA-1 mediated disorder or a TNF- alpha mediated disorder, including cartilage damage, degenerative cartilaginous disorders like rheumatoid arthritis, juvenile chronic arthritis and osteoarthritis, spondyloarthropathy, psoriasis, systemic lupus erythematosus, multiple sclerosis, diabetes, asthma, uveitis and inflammatory bowel disease, particularly Crohn's disease.
Patent NZ-521441-A (NZ)
Title: Pharmaceutical compositions
Inventor: KALB OSKAR
IPC: A61K9/22
Filed: 2001-04-11
Abstract: Pharmaceutical compositions comprising fluvastatin, HPMC and optionally other pharmaceutical excipients, which are colour-stable upon prolonged periods of storage e.g. a storage over more than 2 years and which are suitable for sustained release are disclosed.
Patent NZ-521711-A (NZ)
Title: Modified oocytes and embryonic non-human stem cells able to be cultured into a variety of differentiated cell types
Inventor: WEST MICHAEL D
IPC: A61K35/12
Filed: 2001-04-16
Abstract: Allochimeric embryonic stem (ES) cells are provided having nuclei from one individual of a species and mitochondria from a different individual of the same species. The ES cells can be used for differentiation into differentiated cell types for therapy or for studying various developmental processes in forming embryos and differentiation.
Patent NZ-522689-A (NZ)
Title: Washing machine with control to indicate suds lock or abnormal condition
Inventor: WHAH KENNETH N
IPC: D06F39/06
Filed: 2000-06-20
Abstract: Control is provided for a rotatable basket washing machine with recirculation. Sensing of inlet valve(s) being on or off for predetermined time(s) is used to indicate suds lock of an abnormal condition.
Patent NZ-524303-A (NZ)
Title: Alpha amylase enzymes with increased stability
Inventor: DAY ANTHONY G
IPC: C12N9/28
Filed: 1996-12-09
Abstract: An alpha-amylase has a modified amino acid sequence by the substitution of an amino acid residue in a precursor amino acid sequence from Bacilus licheniformis. The amino acid residue differs from a corresponding amino acid residue in a less stable but homologous alpha-amylase preferably from Bacilus stearothermophilus, Bacilus subtilis or Bacilus amyloliquefaciens. The substitution is selected as described following: M15T/A33S/H133Y /N 188S/A209V; Ml ST/D28N/A33S/H I 33Y/N 188S/A209V; M15T/A52S/H133Y/N188S/A209V; M15T/A52S/H133Y/N188S/A209V/L230F; M15T/S85D/H133Y/N188S/A209V; M15T/N96Q/H133Y/N188S/A209V; MI ST/N96Q/H 1 33Y/N 188S/A209V/1479T; M15T/H 133Y/S148N/N 88S/A209V; M15T/H133Y/S148N/N188S/A209V/A379S; M15T/H 33Y/S 148 N/NI 88S/A209V/G433D; M 15T/H 33Y/N 1 88S/A209V/A379S; M1ST/H 133Y/N 188S/A209V/A21 OS/T322A/A379S. The alpha-amylase with a modified amino acid sequence has an altered stability compared to precursor amino acid sequence. A method for the liquefaction of starch comprising the steps of: (a) preparing an aqueous solution of starch; and (b) contacting the aqueous solution of starch with the alpha-amylase. A detergent composition and a feed additive composition comprising the modified alpha-amylase as described. (62) Divided out of 513415
Patent NZ-526189-A (NZ)
Title: Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors in warm-blooded animals
Inventor: GEORGES GUY
IPC: A61P43/00
Filed: 2001-12-21
Abstract: Compounds of the formula (I) their enantiomers, diastereoisomers, racemates and mixtures thereof and pharmaceutically acceptable salts that have histone deacetylase (HDAC) inhibitor activity and anti-cell proliferation activity such as anti-cancer activity and their manufacturing process is disclosed, wherein A, R1, R2 and X are as defined in the specification.
Patent NZ-526871-A (NZ)
Title: Pharmaceutical dosage forms of epothilones for oral administration
Inventor: BANDYOPADHYAY REBANTA
IPC: A61K47/02
Filed: 2002-01-22
Abstract: Disclosed herein is a use of one or more epothilones or epothilone analogs of formula (Ia) or (Ib) for the manufacture of a medicament for increasing the bioavailability of orally administered epothilones or epothilone analogs, wherein the variables are as defined in the specification. Pharmaceutical compositions, pharmaceutical dosage forms, and kits for increasing the bioavailability of orally administered epothilones or epothilone analogs are also disclosed.
Patent NZ-527567-A (NZ)
Title: Method of diminishing the size of the cross section of an opening of a hollow device located in a flow pipe
Inventor: DE ALMEIRA ALCINO RESENDE
IPC: F16L55/18
Filed: 2001-12-28
Abstract: A method of diminishing the size of the cross section of an opening of a first hollow device (3) is disclosed. The first hollow device is located in an undersea flow pipe (1) through which passes a fluid flow. First a second hollow device is inserted into said undersea flow pipe, the second hollow device having a leading portion (45A) and a trailing portion (45B). Next a foam pig (4) is inserted immediately after the second hollow device. Urged by the flow, the foam pig displaces the second hollow device along the undersea flow pipe, until the latter encounters the first hollow device. The leading portion of the second hollow device is then inserted into the opening of the first device, thereby diminishing the size of the cross section of this opening.
Patent NZ-529082-A (NZ)
Title: Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
Inventor: SUH KWEE-HYUN
IPC: A61K31/7052
Filed: 2002-04-25
Abstract: A clathrate compound of azithromycin hydrate with 1,2-propyleneglycol which is much less hygroscopic than azithromycin hydrate or crystals known in the art is disclosed. This clathrate compound can be useful for the preparation of a medicine for treating various microbial infections.
Patent NZ-531662-A (NZ)
Title: Pro 1293 polypeptides and sequences thereof with homology to an immunoglobulin heavy chain variable region protein
Inventor: BAKER KEVIN
IPC: C07K16/18
Filed: 1999-09-01
Abstract: An isolated nucleic acid having at least 80% sequence identity to a nucleotide sequence that encodes a polypeptide designated PRO1293 comprising the amino acid sequence SEQ ID NO:77 is described. Preferably the nucleic acid comprises the sequence of SEQ ID NO:76 or is that deposited under accession number ATCC 203292. Vectors, isolated host cells, processes for preparing the polypeptide, pharmaceutical compositions and antibodies are also described.
Patent NZ-535168-A (NZ)
Title: Process for synthesizing chiral N-aryl piperazines
Inventor: FEIGELSON GREGG BRIAN
IPC: C07D405/12
Filed: 2003-03-10
Abstract: Disclosed is a process for formation of N-aryl piperazines with chiral side-chains having the structure shown in formula (I), and for making intermediate compounds therefore. In this process chirality is introduced at the piperazine ring formation step and 2-aminopyridyl substitution is incorporated via displacement. The resulting N-NÆ-disubstituted piperazines act on the central nervous system at 5HT receptors.
Patent NZ-535636-A (NZ)
Title: Ophthalmic solutions containing tetrazole derivatives
Inventor: UNEDA TAKESHI
IPC: A61K31/4178
Filed: 2003-03-10
Abstract: An ophthalmic solution comprising: a compound of general formula (i); a cationic antiseptic agent, such as a quaternary ammonium salt, preferably benzalkonium chloride or cetrimide ;and a basic amine compound such as tromtamol, lidocaine or nicotinamide.
Patent NZ-535928-A (NZ)
Title: Determining the ratio of prototype nucleotides to predetermined nucleotides, which is preferably greater than 1:1, by doping in walk-through mutagenesis
Inventor: CREA ROBERTO
IPC: C12Q1/68
Filed: 2003-04-16
Abstract: A method of walk-through mutagenesis of a nucleic acid encoding a prototype polypeptide of interest is described. The method comprising selecting a predetermined amino acid and one or more target regions of the polypeptide, and synthesizing a mixture of oligonucleotides containing at each sequence position in the target region, either a prototype nucleotide that is required for synthesis of the prototype amino acid of the polypeptide, or a predetermined nucleotide that is required for synthesis of the predetermined amino acid, in which during the synthesis, the ratio of available prototype nucleotides, to available predetermined nucleotides, is greater than 1:1.
Patent NZ-538133-A (NZ)
Title: A batten
Inventor: NICHOLLS KEITH GORDON
IPC: E04D12/00
Filed: 2005-02-09
Abstract: A batten (10) to be secured to a frame (11) by a threaded fastener (12). The batten is of a channeled configuration and includes a pair of longitudinally extending mounted flanges (17, 18) that are to be attached to the frame. Spaced from the flanges are further flanges (23, 24) adapted to be sealingly attached to sheets (13, 14). (62) Addition to 530605
Patent NZ-542869-A (NZ)
Title: Partial oxidation reformer-reforming exchanger arrangement
Inventor: KNEZ STANISLAUS A
IPC: C01B3/48
Filed: 2004-03-16
Abstract: Disclosed are a process for preparing syngas, an apparatus for producing syngas and syngas prepared by the said process. The process comprises partially oxidizing a first hydrocarbon portion with oxygen in a partial oxidation reactor to produce a first reactor effluent; cooling the first reactor effluent to a temperature between 650°C and 1000°C; supplying the first reactor effluent to a reforming exchanger; passing a second hydrocarbon portion with steam through a catalyst zone in the reforming exchanger to form a second reactor effluent; discharging the second reactor effluent from the catalyst zone to form an admixture with the first reactor effluent; passing the admixture across the catalyst zone in indirect heat exchange therewith to cool the admixture and heat the catalyst zone; collecting the cooled admixture from the reforming exchanger.
Patent NZ-545132-A (NZ)
Title: Spiro[1-azabicyclo[2.2.2.]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
Inventor: CHANG HUI-FANG
IPC: A61P25/00
Filed: 2004-07-06
Abstract: Disclosed are azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives in accord with formula I and pharmaceutically-acceptable salts thereof, wherein: Q is a moiety of formula II, -A- is selected from -O-, -S-, or -NR1-, or is a bond directly connecting Ar1 and Ar2; Ar1 is selected from formula III or IV, and wherein the other substituents are defined herein. Also disclosed is a pharmaceutical composition comprising one of the above compounds, an enantiomer thereof or a pharmaceutically-acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier. The use of a compound as defined above, in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which activation of the a7 nicotinic receptor is beneficial, neurological disorders, psychotic disorders, intellectual impairment disorders, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, mania or manic depression, Parkinson's disease, Huntington's disease, Tourettes syndrome, or neurodegenerative disorders in which there is loss of cholinergic synapses as also disclosed. In addition, the use of these compounds in the manufacture of a medicament for the prophylaxis jetlag, pain, ulcerative colitis, or for facilitating the cessation of smoking or the treatment of nicotine addiction or craving including that resulting from exposure to products containing nicotine is further disclosed.
Patent NZ-548598-A (NZ)
Title: Decorative stone
Inventor: RAE HAMISH SIMON
Filed: 2006-07-18
Abstract: A method of applying an inlaid design to the curved surface of a stone including: providing a stone with at least one recess; and in situ casting of the material of the inlaid design, where the at least one recess includes a means for retaining the material when cast. A decorative stone item with an in situ cast inlay in a curved surface where the recess includes a means for retaining the cast inlaid material is also disclosed.
Patent NZ-550406-A (NZ)
Title: X-ray apparatus for inspecting food items that have been formed to a uniform thickness to detect the nature, quantity, and location of undesired foreign material within the food item
Inventor: ERLINGSSON VIDAR
IPC: G01N23/02
Filed: 2005-03-10
Abstract: A method and apparatus for inspecting food items is disclosed. The apparatus comprises a conveyer for conveying food items in a predetermined direction, and an X-ray apparatus for generating a uniform X-ray attenuation image of the food items. The apparatus further comprises a means for forming the food items into a shape of uniform thickness, an X-ray emitter for emitting X-rays through the food items as they are conveyed by the conveyer, an X-ray sensor for collecting X-rays after penetrating through the food items, and a processing means adapted to store and/or process X-ray image data.
Patent NZ-552576-A (NZ)
Title: Salt adjuvant-containing gel-forming free flowing compositions in a powder form for transdermal delivery from a needless syringe
Inventor: MAA YUH-FUN
IPC: A61K39/29
Filed: 2001-06-08
Abstract: A gel-forming free-flowing powder for use as a vaccine is prepared by spray freeze-drying an aqueous suspension that contains an antigen adsorbed to an aluminium salt or calcium salt adjuvant, a saccharide, an amino acid or a salt thereof, and a colloidal substance. Processes for forming these powder compositions are described, as well as methods of using the compositions in a vaccination procedure.